Objective
This joint ISPOR – SMDM task force will update the 2012 Model Transparency and Validation: a Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. It will solely focus on good practice guidance on model validation for health economic modelers and users, including HTA assessors, HEOR experts and evidence review bodies.
Rationale
Since the TFR7 publication in 2012, the health economics modeling landscape, and that of data science in general, have substantially changed. Changes include 1) the development of more complex economic models, 2) modeling habits (e.g., the use of R in economic modeling has increased), 3) the publication of several model transparency/validation-specific tools, 4) more complex statistical methods being applied for the estimation of model-parameters, 5) the increasing use of open-source models or real-world data in the modeling process, and finally, 6) the advent of AI.
Furthermore, there is a wide range of variation regarding validation requirements between country-specific published pharmacoeconomic (PE) recommendations, PE guidelines or submission guidelines. In addition to the lack of consensus on validation requirements, there is a lack of consensus on terminology. Addressing these issues will address important gaps in guidance and encourage model validation and its reporting in studies.